Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Abnormal Proliferation02:23

Abnormal Proliferation

4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

6.4K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.4K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

6.8K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

A ROS-responsive supramolecular peptide hydrogel attenuates rheumatoid arthritis by modulating synoviocyte activity and inflammatory microenvironments.

Journal of materials chemistry. B·2026
Same author

From China's Multicenter Prospective Cohort: Right Ventricular Afterload and Prognosis in Hospitalized Patients with Acute Exacerbation of COPD.

International journal of chronic obstructive pulmonary disease·2026
Same author

The Enhancing Effect of Diminishing-Cues Retrieval Practice on the Learning of Difficult English Vocabulary.

Journal of psycholinguistic research·2026
Same author

Efficacy of plant extracts in heart failure patients: a systematic review and network meta-analysis.

BMC cardiovascular disorders·2026
Same author

Urothelial barrier alterations and urinary tract infection susceptibility after voiding cystourethrography: evidence from pediatric cohorts and experimental models.

Pediatric research·2026
Same author

When Scarcity Meets Sustainability: Consumer Preferences for Recycled Products.

Behavioral sciences (Basel, Switzerland)·2026

相关实验视频

Updated: Sep 10, 2025

Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice
10:13

Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice

Published on: August 12, 2014

13.5K

通过 P38 MAPK 途径向 TXN1 诱导结质瘤细胞的 G2M 阶段停止和亡

Lu Zhou1, Hongsheng Liang2, Chenyi Nie1

  • 1Northeast Agricultural University, Harbin, 150000, China.

Applied biochemistry and biotechnology
|August 20, 2025
PubMed
概括

在质瘤细胞中抑制TXN1激活ASK1/ P38MAPK通路,导致细胞循环停止和细胞亡. 这一发现为改善质瘤患者预后提供了潜在的治疗策略.

关键词:
细胞亡G2/M 其他质瘤P38 MAPK 其他其他类型

更多相关视频

Translational Orthotopic Models of Glioblastoma Multiforme
07:37

Translational Orthotopic Models of Glioblastoma Multiforme

Published on: February 17, 2023

3.0K
Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
12:52

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

15.9K

相关实验视频

Last Updated: Sep 10, 2025

Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice
10:13

Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice

Published on: August 12, 2014

13.5K
Translational Orthotopic Models of Glioblastoma Multiforme
07:37

Translational Orthotopic Models of Glioblastoma Multiforme

Published on: February 17, 2023

3.0K
Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
12:52

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

15.9K

科学领域:

  • 癌症学
  • 分子生物学
  • 细胞生物学

背景情况:

  • 质瘤是一种侵袭性脑瘤,在化疗后的预后不佳,原因是细胞抗亡.
  • 针对分子机制对于有效治疗质瘤至关重要.

研究的目的:

  • 研究TXN1在质瘤细胞增殖和亡中的作用.
  • 为了阐明TXN1在质瘤中影响的分子通路.

主要方法:

  • 生物信息学预测和TXN1表达的临床组织验证.
  • 在晶瘤细胞中使用晶病毒介导的TXN1抑制的试验.
  • 通过MTT,流细胞测量,免疫光,西部斑块和qRT-PCR分析细胞周期,细胞灭亡和P38 MAPK通路活性.
  • 使用裸体老鼠异种移植和免疫组织化学的体内研究.

主要成果:

  • TXN1表达与质瘤恶性和患者预后不佳相关.
  • 抑制TXN1诱导G2/ M细胞循环停止和亡的增加.
  • 减少TXN1激活了ASK1/ P38 MAPK通路,导致线粒体损伤.
  • 在质瘤细胞中抑制TXN1逆转了质瘤抵抗.

结论:

  • 抑制TXN1可激活ASK1/ P38MAPK通路,从而诱导质瘤细胞循环停止和细胞亡.
  • 向TXN1是克服恶性质瘤化学抵抗的一个有希望的策略.
  • 与TXN1抑制剂的联合治疗可以改善质瘤患者的临床结果.